Literature DB >> 15552546

The role of monoamine oxidase inhibitors in current psychiatric practice.

Jess G Fiedorowicz1, Karen L Swartz.   

Abstract

The use of monoamine oxidase inhibitors (MAOIs) by psychiatrists has declined over the past several decades with the expansion of psychiatrists' pharmacologic armamentarium. This trend has also been driven by concern about food and drug interactions and side effects, as well as waning physician experience with these medications. Many psychiatrists, in fact, never prescribe MAOIs. Recent research has liberalized the MAOI diet and identified symptom presentations more likely to respond to these medications. Thus, clinicians must continue to familiarize themselves with the properties of and indications for prescribing MAOIs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15552546      PMCID: PMC2075358          DOI: 10.1097/00131746-200407000-00005

Source DB:  PubMed          Journal:  J Psychiatr Pract        ISSN: 1527-4160            Impact factor:   1.325


  115 in total

1.  Mysterious MAOI hypertensive episodes.

Authors:  L S Linet
Journal:  J Clin Psychiatry       Date:  1986-11       Impact factor: 4.384

2.  Forms of atypical depression and their response to antidepressant drugs.

Authors:  J Davidson; S Pelton
Journal:  Psychiatry Res       Date:  1986-02       Impact factor: 3.222

3.  Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly.

Authors:  A Georgotas; R E McCue; W Hapworth; E Friedman; O M Kim; J Welkowitz; I Chang; T B Cooper
Journal:  Biol Psychiatry       Date:  1986-10       Impact factor: 13.382

4.  Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor antidepressant.

Authors:  P J McGrath; J W Stewart; W Harrison; F M Quitkin
Journal:  Psychopharmacol Bull       Date:  1987

5.  Response of depressive symptoms to nortriptyline, phenelzine and placebo.

Authors:  A Georgotas; R E McCue; E Friedman; T B Cooper
Journal:  Br J Psychiatry       Date:  1987-07       Impact factor: 9.319

6.  An outpatient evaluation of phenelzine and imipramine.

Authors:  J Davidson; D Raft; S Pelton
Journal:  J Clin Psychiatry       Date:  1987-04       Impact factor: 4.384

7.  An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.

Authors:  J R Davidson; E L Giller; S Zisook; J E Overall
Journal:  Arch Gen Psychiatry       Date:  1988-02

8.  Antidepressant specificity in atypical depression.

Authors:  M R Liebowitz; F M Quitkin; J W Stewart; P J McGrath; W M Harrison; J S Markowitz; J G Rabkin; E Tricamo; D M Goetz; D F Klein
Journal:  Arch Gen Psychiatry       Date:  1988-02

9.  Refractory depression treated with high doses of monoamine oxidase inhibitor.

Authors:  B H Guze; L R Baxter; J Rego
Journal:  J Clin Psychiatry       Date:  1987-01       Impact factor: 4.384

Review 10.  'Spontaneous' hypertensive episodes with monoamine oxidase inhibitors.

Authors:  B Fallon; B Foote; B T Walsh; S P Roose
Journal:  J Clin Psychiatry       Date:  1988-04       Impact factor: 4.384

View more
  28 in total

1.  The selegiline transdermal system (emsam): a therapeutic option for the treatment of major depressive disorder.

Authors:  Lois Jessen; Lawrence J Kovalick; Albert J Azzaro
Journal:  P T       Date:  2008-04

Review 2.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

Review 3.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

Review 4.  Type A monoamine oxidase and serotonin are coordinately involved in depressive disorders: from neurotransmitter imbalance to impaired neurogenesis.

Authors:  Makoto Naoi; Wakako Maruyama; Masayo Shamoto-Nagai
Journal:  J Neural Transm (Vienna)       Date:  2017-03-14       Impact factor: 3.575

5.  Pharmaceutical Interventions in Chronic Fatigue Syndrome: A Literature-based Commentary.

Authors:  Spencer Richman; Matthew C Morris; Gordon Broderick; Travis J A Craddock; Nancy G Klimas; Mary Ann Fletcher
Journal:  Clin Ther       Date:  2019-03-11       Impact factor: 3.393

6.  A Forward Chemical Genetic Screen Reveals Gut Microbiota Metabolites That Modulate Host Physiology.

Authors:  Haiwei Chen; Phu-Khat Nwe; Yi Yang; Connor E Rosen; Agata A Bielecka; Manik Kuchroo; Gary W Cline; Andrew C Kruse; Aaron M Ring; Jason M Crawford; Noah W Palm
Journal:  Cell       Date:  2019-04-18       Impact factor: 41.582

7.  Reducing the Burden of Difficult-to-Treat Major Depressive Disorder: Revisiting Monoamine Oxidase Inhibitor Therapy.

Authors:  Larry Culpepper
Journal:  Prim Care Companion CNS Disord       Date:  2013-10-31

8.  A review of the literature on the selegiline transdermal system: an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression.

Authors:  Larry Culpepper; Lawrence J Kovalick
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

Review 9.  The role of oxidative stress in anxiety disorder: cause or consequence?

Authors:  Alessandra das Graças Fedoce; Frederico Ferreira; Robert G Bota; Vicent Bonet-Costa; Patrick Y Sun; Kelvin J A Davies
Journal:  Free Radic Res       Date:  2018-06-04

10.  Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively.

Authors:  Samuel R Chamberlain; David S Baldwin
Journal:  CNS Drugs       Date:  2021-07-09       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.